2,111
Views
23
CrossRef citations to date
0
Altmetric
Research Paper

A comparative study of affibody, panitumumab, and EGF for near-infrared fluorescence imaging of EGFR- and EGFRvIII-expressing tumors

, , , &
Pages 185-193 | Received 18 Jun 2013, Accepted 06 Oct 2013, Published online: 01 Nov 2013

Figures & data

Figure 1. Microscopic examination of Aff800 (50 nM), Pan800 (10 nM), and EGF800 (50 nM) binding and uptake by F98-EGFR (A) and F98-vIII (B) cells. DAPI was used to stain the nuclei. Scale bar: 10 μm.

Figure 1. Microscopic examination of Aff800 (50 nM), Pan800 (10 nM), and EGF800 (50 nM) binding and uptake by F98-EGFR (A) and F98-vIII (B) cells. DAPI was used to stain the nuclei. Scale bar: 10 μm.

Figure 2. Concentration-dependent binding and uptake of different probes. Different concentrations of Aff800, Pan800, EGF800 and free IRDye 800CW (IR800) were incubated with F98-EGFR (A), F98-vIII (B), and F98-p (C). The fluorescence signals were determined after removal of unbound probes (n = 3 for each data point).

Figure 2. Concentration-dependent binding and uptake of different probes. Different concentrations of Aff800, Pan800, EGF800 and free IRDye 800CW (IR800) were incubated with F98-EGFR (A), F98-vIII (B), and F98-p (C). The fluorescence signals were determined after removal of unbound probes (n = 3 for each data point).

Figure 3. Competition of Aff800, Pan800, and EGF800 binding by unlabeled molecules. Aff800 (A and B), Pan800 (C and D), and EGF800 (E and F) were incubated with F98-EGFR and F98-vIII in the presence of different concentrations (ranging from 0.49 to 500 nM) of unlabeled nanobody 7D12, affibody, EGF, or panitumumab. The fluorescence signals were determined after removal of unbound probes (n = 3 for each data point).

Figure 3. Competition of Aff800, Pan800, and EGF800 binding by unlabeled molecules. Aff800 (A and B), Pan800 (C and D), and EGF800 (E and F) were incubated with F98-EGFR and F98-vIII in the presence of different concentrations (ranging from 0.49 to 500 nM) of unlabeled nanobody 7D12, affibody, EGF, or panitumumab. The fluorescence signals were determined after removal of unbound probes (n = 3 for each data point).

Figure 4. Optical imaging of mice bearing F98-p, F98-EGFR, and F98-vIII xenograft tumors. (A) Representative whole mouse images (dorsal view) acquired at 24 h after administration of Aff800 (left), Pan800 (center), and EGF800 (right). The white arrows indicate the tumors: 1, F98-p; 2, F98-EGFR; 3, F98-vIII. The red arrow heads indicate kidneys. Kidneys of Pan800-injected mouse were not marked as they were not visible. Note that the scales for fluorescence signal intensities are adjusted individually for each probe. (B) Ex vivo imaging of tissue distribution of mice injected with Aff800 (upper left), Pan800 (upper right), and EGF800 (lower left). The layout of different tissues is illustrated in the lower right corner.

Figure 4. Optical imaging of mice bearing F98-p, F98-EGFR, and F98-vIII xenograft tumors. (A) Representative whole mouse images (dorsal view) acquired at 24 h after administration of Aff800 (left), Pan800 (center), and EGF800 (right). The white arrows indicate the tumors: 1, F98-p; 2, F98-EGFR; 3, F98-vIII. The red arrow heads indicate kidneys. Kidneys of Pan800-injected mouse were not marked as they were not visible. Note that the scales for fluorescence signal intensities are adjusted individually for each probe. (B) Ex vivo imaging of tissue distribution of mice injected with Aff800 (upper left), Pan800 (upper right), and EGF800 (lower left). The layout of different tissues is illustrated in the lower right corner.

Figure 5. Analysis of tumor tissue lysates. Tumor tissue samples from mice injected with Aff800 (left), Pan800 (center), and EGF800 (right) were homogenized in RIPA buffer and analyzed on a non-reducing BIS-TRIS gel. F98-p, F98-EGFR, and F98-vIII tumor lysates (lanes 2, 3, and 4) were run on the gel together with the respective pure imaging agent (lane 1) and free dye IRDye 800CW (lane 5). The protein marker was shown on the left side (molecular weights in kDa from top to bottom: 250, 150, 100, 75, 50, 37, 25, 20, 15, 10).

Figure 5. Analysis of tumor tissue lysates. Tumor tissue samples from mice injected with Aff800 (left), Pan800 (center), and EGF800 (right) were homogenized in RIPA buffer and analyzed on a non-reducing BIS-TRIS gel. F98-p, F98-EGFR, and F98-vIII tumor lysates (lanes 2, 3, and 4) were run on the gel together with the respective pure imaging agent (lane 1) and free dye IRDye 800CW (lane 5). The protein marker was shown on the left side (molecular weights in kDa from top to bottom: 250, 150, 100, 75, 50, 37, 25, 20, 15, 10).
Supplemental material

Additional material

Download Zip (138.8 KB)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.